Loading
Treatment of Major Depression · Journal article
Psychiatry International · September 1, 2026
A consensus or society position rather than new primary data.
This structured narrative review identifies recurring methodological, regulatory, and implementation weaknesses across ketamine and psilocybin clinical trials, spanning protocol design, masking, safety monitoring, participant diversity, and informed consent. The authors conclude that responsible clinical translation requires integrated evidence addressing efficacy, causal validity, safety, treatment context, and service delivery, with ketamine further advanced than psilocybin.
Structured narrative review. Clinical trials on ketamine and psilocybin for major depressive disorder and treatment-resistant depression; focus on trial design and implementation characteristics.. Intervention: Structured review of ketamine-family compounds and psilocybin trial methodology, regulatory alignment, and implementation requirements..
Six author-led studies identified recurring weaknesses in protocol design, dose and endpoint selection, masking and expectancy assessment, safety monitoring and long-term follow-up Reporting gaps noted in psychological support, treatment setting, and participant representativeness across the literature Consent comprehensibility identified as a systematic weakness
Six author-led studies identified recurring weaknesses in protocol design, dose and endpoint selection, masking and expectancy assessment, safety monitoring and long-term follow-up
Clinicians and researchers designing or implementing ketamine or psilocybin trials should use this framework to address identified methodological gaps—particularly in masking, expectancy control, safety monitoring, long-term follow-up, diversity, and informed consent—before proceeding to clinical practice. The assessment that psilocybin remains earlier in development should inform expectations about evidence maturity and regulatory readiness.
A structured narrative review synthesizing methodological and regulatory challenges across ketamine and psilocybin trials, identifying systemic weaknesses in trial design and implementation readiness rather than reporting a primary efficacy result.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians and researchers designing or implementing ketamine or psilocybin trials should use this framework to address identified methodological gaps—particularly in masking, expectancy control, safety monitoring, long-term follow-up, diversity, and informed consent—before proceeding to clinical practice. The assessment that psilocybin remains earlier in development should inform expectations about evidence maturity and regulatory readiness.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Major depressive disorder (MDD) and treatment-resistant depression (TRD) continue to drive interest in ketamine-family compounds and psilocybin, but antidepressant efficacy alone does not establish whether these interventions can be evaluated reliably or implemented responsibly. We conducted a structured narrative review using targeted PubMed/MEDLINE searches through 21 July 2026, hand-searching of reference lists, and review of current regulatory documents. Six studies conducted by the authors formed the empirical foundation, covering trial protocols, dose–response relationships, treatment context reporting, regulatory alignment, participant diversity, and informed-consent readability. Findings were synthesized across regulatory, internal methodological, contextual, external, ethical, and implementation domains. The six studies identified recurring weaknesses in protocol design, dose and endpoint selection, masking and expectancy assessment, safety monitoring and long-term follow-up, reporting of psychological support and treatment setting, participant representativeness, and consent comprehensibility. The wider literature broadly supports these conclusions. Ketamine has a more mature evidence and implementation base, whereas psilocybin remains at an earlier stage of clinical development. Responsible translation into clinical practice therefore requires integrated evidence addressing efficacy, causal validity, safety, treatment context, diversity, informed consent, durability, and service delivery, while clearly distinguishing legal requirements, regulatory guidance, evidence-based methodological practices, and the authors’ recommendations.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.